Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors - PubMed (original) (raw)
. 2004 Aug 10;111(1):32-42.
doi: 10.1002/ijc.20236.
Affiliations
- PMID: 15185340
- DOI: 10.1002/ijc.20236
Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors
T Charis Wagner et al. Int J Cancer. 2004.
Abstract
In addition to antiviral effects, Type I interferons (IFN) have potent antiproliferative and immunomodulatory activities. Because of these properties IFNs have been evaluated as therapeutics for the treatment of a number of human diseases, including cancer. Currently, IFNs have been shown to be efficacious for the treatment of only a select number of cancers. The reason for this is unclear. Recent evidence has demonstrated that some cancer cell types seem to be defective in their ability to respond to IFN. It has been suggested that defects in IFN signaling is one mechanism by which cancer cells escape responsiveness to Type I IFNs and growth control in general. We report that transfection and enhanced expression of the Type I IFN receptor chain (IFNAR2c) in 3 different human cancer cell lines markedly increases the sensitivity of these cells to the antiproliferative effects of IFNs. In cancer cells transfected with IFNAR2c, dose response curves demonstrate a significant decrease in the concentrations of IFN required to achieve maximum cell death. Furthermore, in these transfected cells, we observe a significant increase in the number of cells undergoing apoptosis, as measured by DNA fragmentation and Caspase 3 activation. In addition, using an in vivo xenograft tumor model we show an increase in the effectiveness of systemically delivered Betaseron in decreasing tumor burden in animals in which solid tumors were generated from IFNAR2c transfected cells. These data show that specific regulation of IFN receptor expression can play a major role in determining the clinical outcome of IFN-based cancer therapeutics by regulating the relative sensitivity of cancer cells to IFN-dependent growth control.
Copyright 2004 Wiley-Liss, Inc.
Similar articles
- Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC. Reu FJ, et al. J Clin Oncol. 2006 Aug 10;24(23):3771-9. doi: 10.1200/JCO.2005.03.4074. Epub 2006 Jun 26. J Clin Oncol. 2006. PMID: 16801630 - Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta.
Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Johns TG, et al. J Natl Cancer Inst. 1992 Aug 5;84(15):1185-90. doi: 10.1093/jnci/84.15.1185. J Natl Cancer Inst. 1992. PMID: 1378904 - Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay.
Schiller JH, Willson JK, Bittner G, Wolberg WH, Hawkins MJ, Borden EC. Schiller JH, et al. J Interferon Res. 1986 Dec;6(6):615-25. doi: 10.1089/jir.1986.6.615. J Interferon Res. 1986. PMID: 2437222 - Potentials of interferon therapy in the treatment of pancreatic cancer.
Booy S, Hofland L, van Eijck C. Booy S, et al. J Interferon Cytokine Res. 2015 May;35(5):327-39. doi: 10.1089/jir.2014.0157. Epub 2014 Dec 31. J Interferon Cytokine Res. 2015. PMID: 25551196 Review. - Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry.
Brierley MM, Fish EN. Brierley MM, et al. J Interferon Cytokine Res. 2002 Aug;22(8):835-45. doi: 10.1089/107999002760274845. J Interferon Cytokine Res. 2002. PMID: 12396722 Review.
Cited by
- Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.
Fuchs SY. Fuchs SY. J Interferon Cytokine Res. 2013 Apr;33(4):211-25. doi: 10.1089/jir.2012.0117. J Interferon Cytokine Res. 2013. PMID: 23570388 Free PMC article. Review. - Optimizing tumor immune response through combination of radiation and immunotherapy.
El Chediak A, Shamseddine A, Bodgi L, Obeid JP, Geara F, Zeidan YH. El Chediak A, et al. Med Oncol. 2017 Aug 21;34(9):165. doi: 10.1007/s12032-017-1025-z. Med Oncol. 2017. PMID: 28828581 Review. - Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance.
Budhwani M, Mazzieri R, Dolcetti R. Budhwani M, et al. Front Oncol. 2018 Aug 21;8:322. doi: 10.3389/fonc.2018.00322. eCollection 2018. Front Oncol. 2018. PMID: 30186768 Free PMC article. Review. - Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection.
Wada H, Nagano H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Sakon M, Wakasa K, Monden M. Wada H, et al. J Gastroenterol. 2007 Jun;42(6):501-6. doi: 10.1007/s00535-007-2028-x. Epub 2007 Jun 29. J Gastroenterol. 2007. PMID: 17671767 - Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells.
Booy S, van Eijck CH, Dogan F, van Koetsveld PM, Hofland LJ. Booy S, et al. J Cell Mol Med. 2014 Mar;18(3):492-502. doi: 10.1111/jcmm.12200. Epub 2014 Jan 25. J Cell Mol Med. 2014. PMID: 24460759 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials